Stone Clinical Laboratories of FL LLC

Stone Clinical Laboratories of FL LLC was paid $99K by Medicaid between Sep 2020 and Sep 2024, across 47 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 43% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Florida

Rank by total paid#105 of 225

Median peer was paid$74K

This provider vs. median1.3×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	1,216	$2K
2021	1,711	$6K
2022	4,078	$50K
2023	8,634	$41K
2024incomplete	2,473	$117.44

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	43%	3,022	1,416	$42K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	17%	693	349	$17K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	9.4%	639	411	$9K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	9.2%	1,510	693	$9K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	4.9%	989	413	$5K
80053	Comprehensive metabolic panel	4.3%	2,109	1,204	$4K
87481		1.9%	61	38	$2K
84443	Thyroid stimulating hormone (TSH)	1.8%	615	421	$2K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.5%	354	239	$2K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.3%	2,168	1,194	$1K
80061	Lipid panel	1.1%	570	364	$1K
80048	Basic metabolic panel (calcium, ionized)	<1%	484	281	$819.53

35 more codes

82607		<1%	305	$583.72
83036	Hemoglobin; glycosylated (A1C)	<1%	663	$486.45
82746		<1%	198	$378.73
87641		<1%	168	$322.04
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	325	$278.11
87640		<1%	294	$237.16
83735		<1%	463	$143.26
84439		<1%	240	$138.50
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	61	$117.44
82728		<1%	69	$89.15
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	48	$70.18
83719		<1%	75	$60.24
87653		<1%	209	$57.63
84466		<1%	49	$41.70
87500		<1%	46	$35.09
85014		<1%	98	$30.63
87563		<1%	53	$28.53
81001		<1%	111	$14.88
83540		<1%	89	$14.80
85007		<1%	106	$12.85
84481		<1%	17	$10.21
85004		<1%	28	$8.11
85027		<1%	21	$7.90
85018		<1%	98	$2.79
87581		0%	265	$0.00
87486		0%	265	$0.00
87511		0%	22	$0.00
87541		0%	99	$0.00
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	0%	26	$0.00
87529		0%	23	$0.00
83550		0%	16	$0.00
82040		0%	44	$0.00
87631		0%	265	$0.00
82465		0%	13	$0.00
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	0%	26	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialRIDGEWAY, CHRISTOPHER (CEO AND FOUNDER)